Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conjugated equine estrogen + medroxyprogesterone acetate is a combination oral hormone therapy used primarily for the treatment of menopausal symptoms such as hot flashes, vaginal changes, and for the prevention of osteoporosis in postmenopausal women. The product combines conjugated estrogens (a mixture derived from natural sources, mainly sodium estrone sulfate and sodium equilin sulfate) with medroxyprogesterone acetate (a synthetic progestin). Conjugated estrogens act as agonists at estrogen receptor to regulate gene expression involved in female sexual development and maintenance of secondary sexual characteristics. Medroxyprogesterone acts as an agonist at progesterone receptor to convert a proliferative endometrium into a secretory one, reducing the risk of endometrial hyperplasia associated with unopposed estrogen therapy. This combination is indicated for women with an intact uterus undergoing menopause[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on conjugated equine estrogen + medroxyprogesterone acetate.